Cilastatin

CHEMBL766 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

358.5 g/mol

LogP

-1.0

Phase

4

A competitive inhibitor of the renal enzyme dehydropeptidase-I that degrades imipenem in the kidney, used exclusively in combination with imipenem to prevent renal inactivation and nephrotoxicity of the antibiotic. It has no intrinsic antibacterial activity of its own. The combination dramatically improves the pharmacokinetic profile and safety of imipenem.

Moleküler Ağırlık

358,5000 g/mol

LogP

-1,00

TPSA

155,00 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Infectious Disease Ovarian Cancer Hematology Oncology Obesity Tuberculosis

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CC1(C)C[C@@H]1C(=O)N/C(=C\CCCCSC[C@H](N)C(=O)O)C(=O)O

InChI

InChI=1S/C16H26N2O5S/c1-16(2)8-10(16)13(19)18-12(15(22)23)6-4-3-5-7-24-9-11(17)14(20)21/h6,10-11H,3-5,7-9,17H2,1-2H3,(H,18,19)(H,20,21)(H,22,23)/b12-6-/t10-,11+/m1/s1

Molecular Formula

C16H26N2O5S

HBD / HBA

4 / 7

Döndürülebilir Bağlar

11

Ağır Atomlar

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A competitive inhibitor of the renal enzyme dehydropeptidase-I that degrades imipenem in the kidney, used exclusively in combination with imipenem to prevent renal inactivation and nephrotoxicity of the antibiotic. It has no intrinsic antibacterial activity of its own. The combination dramatically improves the pharmacokinetic profile and safety of imipenem.

Yes, Cilastatin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL766. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6435415. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Cilastatin PillFYI'da

Yapı

Hızlı Veriler

Formül: C16H26N2O5S
Eş Anlamlılar: 3

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.